<DOC>
	<DOC>NCT00956982</DOC>
	<brief_summary>The purpose of this study is to analyze the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) alpha-2b plus ribavirin (RBV) for older Japanese patients (≧65years old) infected with hepatitis C virus (HCV) compared with younger patients(&lt; 65 years old).</brief_summary>
	<brief_title>PEG-IFN Plus Ribavirin Combination Therapy for Older Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>A prospective study of 2270 Japanese patients aged 18 years or older treated with PEGIFN alpha2b plus RBV was done between December 2004 and July 2008. All positive for both antibody to HCV and HCVRNA for over six months and were enrolled. Clinical or biochemical evidence of hepatic decompensation. Advanced cirrhosis identified by large esophageal varices (F2 or F3). History of gastrointestinal bleeding, ascites, encephalopathy, or hepatocellular carcinoma. Hemoglobin level &lt; 11.5g/L, white blood cell count &lt; 3×10９/Ｌ，and platelet count &lt; 50×10９/Ｌ. Concomitant liver disease other than hepatitis C(hepatitis B surface antigen positive or HIV positive). Excessive active alcohol consumption &gt; 60 g/day or drug abuse. Severe psychiatric disease. Antiviral or corticosteroid therapy within 12 months prior to the enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Hepatitis C Virus Pegylated Interferon Ribavirin Older</keyword>
</DOC>